Member Info for LiveLongnProsper

The volume is in t6esting individuals regularly ... largely through LF tests ... These LF testst ARE coming to market ...
GLA

But broadcasting now from the future …
10 mins to buy, or sell?
Though from what he’s just said, I think I’ll just close up the hermetically sealed bunker and go to internal air and power. Think I’ll watch Utopia …
GLA

@PL75, haha, yes was there in June, plenty of newbies though, and really good history lesson!
GLA

Klaus ...
Specificity overlooked, 95% (implied) not good enough.
David ...
Best tests - high sens / spec. Antigen test the bias will be sens and neg predictive value, ideally both (sens / spec) high.
Klaus ..
Agrees, don't want false negatives. Spec a big hurdle.
GLA

Klaus ...
Need Sens and Spec better than before, better than one's on the market.
Many surprises appearing in (implied) nature of virus.
Darren (Sona) ...
Seems to have said not yet achieved acceptable level of detection?
GLA

Brendan again.
Risk of accelerated process.
Need proper development methodology (that's what DCN do - Cytiva competitor).
Need to adapt to changing use and performance requirements.
One of biggest gaps is knowledge, e.g. scaling manufacturing (good that we have BBI and Abingdon).
Time to result critical - benefit of LFT - result in minutes. Particularly antigen testing.
Mass pop screening in US - LFT provides only available solution.
GLA

Darren Rowles - Sona
Mentioned the Avacta test before the Sona one - which is Nasopharyngeal swab (he's a bitworried!).
CMO (contract manufacturing organisations) a constraint. Tech transfer normally 6 months. Anticipates 100's millions of tests.
GLA

https://events.labroots.com/event/DiagnosticsVirtualSummitAglobalperspective/en-us#!/Auditorium/n890690
Registration required.

David Wilson (Awacta) ...
Need test that can b easily deployed in community, primary care and consumer settings.
LFT the only format for mass screening.
Demand for testing will not go away for a long time, testing in significant numbers for at least 12 months.
FDA and MHRA looking to accelerate approval process (yes, he said FDA).
Without these tools (LFT tests) will be difficult to get society back to normal.
Because of demand, supply under strain - tests, components - supply-chain under strain.
GLA

Great intro from Brendan O'Farrell - DCN. Klaus just confirming confirming (as said by Brendan) antibody tests not the way to go. Need antigen tests, but warning about 'user errors' in self-sample test . Need sensitivity better than 95%.
Will need to test for a very long time.
This is good stuff. David on now.
GLA
GLA

Spread either side 167/171, draw your own conclusions.
GLA

and again ...
Another PhD researching areas of cancer treatment using Affimers.
https://www.findaphd.com/phds/project/mrc-dimen-doctoral-training-partnership-developing-protein-tools-to-target-dna-damage-response-and-repair-in-cancer-cells/?p114527
Post seems to have been oversubscribed with applications, the word is spreading.
GLA

OK, came on late due to LSE 'blackout'.

@Graham59, good find, forgive me for re-phrasing the heading (for better balance!).
Alastair Smith, CEO of Avacta, comments: "Cytiva has been a key partner in developing a rapid coronavirus antigen test and we continue to work closely with them, and our manufacturing partners, to finalise the test in a format suitable for massively scaled-up manufacturing processes to meet the anticipated demand."
Particularly like the "massively scaled-up" bit.
GLA

Yep, he knows what coming, and even bought back after his recent (small) disposal ...
Oct 27 2020, 08:19 161.40 1 159.00 163.00 Buy £1.614 O
Haha
GLA

Just seem to be everywhere ...
https://www.nc3rs.org.uk/direct-replacement-secondary-antibodies-affimer-proteins
Grant for research aimed at replacing ‘secondary antibodies’ (used in medical research and diagnostics) – which are polyclonal and, apparently, grown in sheep, donkeys and goats. Eliminate cross-reactivity and batch-to-batch inconsistencies, not to mention eliminating the ethical issues around use of animals.
Story gets better and better, Affimers seem to be the future. Wake up ‘big pharma’.
GLA

Seems almost certain that AVACTA are very visible to government inside the NDA protected space, so I would expect that co. directors are being very careful. Would not be good publicity after we get through approvals and the sp rockets to see a bunch of large director sells. I stress large, would expect to see some sells, perfectly reasonable. In the meantime Al needs to complete on his house and choses to take ‘a few bob’ out before the real deal. Seems like an honest move to me (also preserves the prospect of becoming a Sir!)
This is a serious company with seemingly 'game-changing' products and a long-term strategy to grow the Diagnostics business and to take the Therapeutics products through clinical programmes – most notably pre|CISION Pro Doxorubicin for targeted chemotherapy. The short to medium-term cash flow from SARS-CoV-2 Antigen tests will enable these programmes to be significantly accelerated, further, and massively, increasing the potential value of the company.
@Intrepidinvestor, the cautionary note, though, should not be disregarded. Personally I think it sensible to sell a few shares to cover some or all of your costs at some point, and I will likely do the same. Timing and approach (particularly an objective assessment of the risk to yourself) is key, and this (for me) is best achieved through a lot of careful research and (at least at the moment) day-to-day monitoring of the company and involved parties.
GLA

And Affimers are 'designed-for-purpose'. So could be generated to detect other viruses.
Growing use in diagnostics, avenues of research include detecting cancer and possibly pre-cancer biomarkers.
Not to mention the potential to directly block the virus.
'Big Pharma' has many £100m's invested in mABs. Watch out, Affimers are coming your way.
GLA
ps expect to be looking for a bigger house soon, haha

Just researching Tom Solomon, who was interviewed on R4 this morning, from the LSTM listing ...
Professor Tom Solomon is Chair of Neurological Science at the University of Liverpool and Director of the National Institute for Health Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections.
So he will no doubt know about Avacta and Affimers for reasons LTH's will understand.
GLA

Interviewing Tom Solomon - Director of Emerging Infections, Liverpool University.
Responding to specific question about buying a test etc. Private test kits £100+, not very good.
"what we're after ideally is a simple home test kit ... like a pregnancy test... but we're not quite there yet ..."
GLA